NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Eledon Pharmaceuticals, Inc. ELDN
14 fiscal years on record · USD · FY2025 reported · SEC filings only
$-45.6M
Growth
—
Revenue, FY2025 · full 14-year series below
Revenue $M
Net income $M
FY2016 · Revenue 0.0 · Net income -5.7
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -63.6%
Each USD of equity lost 64 cents this year.
The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | · | · | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.52 | · | · | −6.16 | −2.33 | −15.72 | −24.42 | −1.56 | −2.30 | −2.46 | −2.01 | −3.60 | −38.02 | −31.09 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −63.6 | −518.4 | · | −93.7 | −19.5 | −22.8 | −133.7 | −82.9 | −156.6 | −14137.5 | −84.8 | −96.6 | · | · |
| Shares out B | 0.08 | 0.06 | 0.02 | 0.01 | 0.01 | 0.02 | 0.00 | 0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 52 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 24 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012